CRISPR gene editing shows promise for treating individuals with a form of inherited blindness

Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the participants treated.

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,Philadelphia ,Mark Pennesi ,Irene Heinz ,Tomass Aleman ,Baisong Mei ,Harvard Medical School ,Hospital Of The University Pennsylvania ,Cell Therapy Institute ,Editas Medicine Inc ,Wk Kellogg Eye Center ,Scheie Eye Institute ,Bascom Palmer Eye Institute ,Ocular Genomics Institute ,Eric Pierce ,Mass Eye ,Mass General Brigham ,Editas Medicine ,New England Journal ,Berman Gund Laboratory ,Retinal Degenerations ,Harvard Medical ,Leber Congenital Amaurosis ,Chief Medical Officer ,General Brigham ,Casey Eye Institute ,Oregon Health ,Science University ,Eye Center ,Irene Heinz Given ,John Laporte Research Professor ,Penn Medicine ,Blindness ,Clinical Trial ,Gene ,Cas9 ,Children ,Rispr ,Ear ,Efficacy ,Eye ,Wood ,Gene Therapy ,Gene Editing ,Enetic ,Enome ,Genome Editing ,Genomics ,Healthcare ,Hearing ,Hospital ,Laboratory ,Medical School ,Medicine ,Neck ,Ophthalmology ,Protein ,Research ,Retinal Degeneration ,Throat ,Vision Loss ,